Skip to content

Effectiveness and Safety of Fu's Subcutaneous Needling Therapy for Novel Coronavirus Infection-Related Symptoms without Fever: A Real-World Study

Effectiveness and Safety of Fu's Subcutaneous Needling Therapy for Novel Coronavirus Infection-Related Symptoms without Fever: A Real-World Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067411
Enrollment
Unknown
Registered
2023-01-06
Start date
2023-01-07
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Infection-Related Symptoms

Interventions

Sponsors

Shandong Provincial Third Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: (1)Age between 18-65 years old, male or female; (2)Patients with novel coronavirus infection confirmed within 28 days; (3)Vital signs of patients are stable; (4)Patients with one or more of the following symptoms that are new and persistent and cannot be explained by other causes and diagnoses:headache[Visual Analogue Scale(VAS)score=4], nasal obstruction, sore throat (VAS score=4), hyposmia, hypogeusia,cough, poor appetite,abdominal distention, abdominal pain (VAS score =4), diarrhea, constipation, fatigue, neck and shoulder pain (VAS score=4), low back pain (VAS score=4), leg pain (VAS score=4); (5)Patients voluntarily to receive FSN treatments and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Exclusion criteria (1)Patients with dyspnea and/or hypoxia; (2)Patients with basic diseases had a tendency to worsen; (3)Patients with serious diseases of liver and kidney, cardiopulmonary, cardiovascular and cerebrovascular diseases; (4)Patients who had participated in or were participating in other clinical studies within one month; (5)Pregnant and lactating women; (6)Patients who could not complete treatment or efficacy evaluation.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale (VAS);Score of the Fatigue Scale (FS-14);Score of the Short-Form McGill Pain Questionnaire (SF-MPQ);Score of the Gastrointestinal Symptom Rating Scale (GSRS);total nasal symptom score (TNSS);Score of EuroQol-5D (EQ-5D);

Countries

China

Contacts

Public ContactBai Tianyu

Shandong Provincial Third Hospital

baitinayu19820217@163.com+86 15168879181

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026